Modifications of α2-Plasmin Inhibitor During Treatments by a Defibrinating Agent
Modifications of α2-Plasmin Inhibitor During Treatments by a Defibrinating Agent
复制标题
去纤维蛋白剂治疗期间 α2-纤溶酶抑制剂的修饰
DOI：
10.1055/s-0039-1684847
复制
发表时间：
1979
影响因子：
6.7
通讯作者：
G. Coscas
中科院分区：
文献类型：
--
作者：
M. Samama;J. Conard;B. Cazenave;A. Derlon;A. Gaudric;G. Coscas
已向8名患有视网膜静脉阻塞的患者施用脱髓鞘剂（Deepinase ®）。以0.5 B的剂量皮下输注脱氢酶。U./ kg/天，持续5天，随后为1 - 2 B.U./ kg，每周两次，另外2周，以便纤维蛋白原水平维持在100 mg/100 ml以下。进行了以下检测：纤维蛋白原、FDP、可溶性复合物、纤溶酶原、α2巨球蛋白、抗凝血酶III、α2-纤溶酶抑制剂（酰胺分解法和Laurell法）、血液和血浆粘度。在治疗前进行，每天重复5天，然后在第8、11、14和21天进行。如前所述，观察到纤维蛋白原、粘度、纤溶酶原减少，FDP和可溶性复合物增加。α2-纤溶酶抑制剂的结果显示降低约50%，Laurell法比酰胺分解法略明显。通过交叉免疫电泳检测到纤溶酶-α2纤溶酶抑制剂复合物以不同的量存在。
A defibrination agent (Defibrase®) has been administered to 8 patients with retinal vein occlusion. Defibrase has been infused sub-cutaneously at a dose of 0.5 B. U./kg/day for 5 days followed by 1 to 2 B.U./kg twice a week, for 2 other weeks, so that fibrinogen level was maintained below 100 mg/100 ml. The tests performed were the following : fibrinogen, FDP, soluble complexes, plasminogen, α2 macroglobulin, antithrombin III, α2-plasmin inhibitor (amidolytic and Laurell methods), blood and plasma viscosity. They have been done before treatment and repeated daily for 5 days and then on the 8th, 11th, 14th and 21st day. A decrease in fibrinogen, viscosity, plasminogen and an increase in FDP and soluble complexes have been observed, as already described. The results of the α2- plasmin inhibitor shows a decrease of about 50 % that is slightly more pronounced by the Laurell method than the amidolytic method. The plasmin-α2 plasmin inhibitor complex detected by crossed immunoelectrophoresis is present in various amounts.